Foliglurax

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Foliglurax
Accession Number
DB15292
Description

Foliglurax is under investigation in clinical trial NCT02639221 (A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects).

Type
Small Molecule
Groups
Investigational
Purchasing individual compounds or compound libraries for your research?
Learn More
Structure
Thumb
Weight
Average: 421.52
Monoisotopic: 421.146012787
Chemical Formula
C23H23N3O3S
Synonyms
Not Available
External IDs
  • PXT002331

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
FR50CP1D6W
CAS number
1883329-53-0
InChI Key
ZTEDNASHAWNBKQ-NCELDCMTSA-N
InChI
InChI=1S/C23H23N3O3S/c27-25-19-13-22(20-14-23-17(15-24-20)5-11-30-23)29-21-4-3-16(12-18(19)21)2-1-6-26-7-9-28-10-8-26/h3-5,11-15,27H,1-2,6-10H2/b25-19+
IUPAC Name
N-[(4E)-6-[3-(morpholin-4-yl)propyl]-2-{thieno[3,2-c]pyridin-6-yl}-4H-chromen-4-ylidene]hydroxylamine
SMILES
O\N=C1/C=C(OC2=C1C=C(CCCN1CCOCC1)C=C2)C1=CC2=C(C=CS2)C=N1

References

General References
Not Available
ChemSpider
64835206
BindingDB
50241580
ChEMBL
CHEMBL4089083
Wikipedia
Foliglurax

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentParkinson's Disease (PD)1
2WithdrawnTreatmentParkinson's Disease (PD)1
1CompletedNot AvailableParkinson's Disease (PD)1
1CompletedTreatmentHealthy Volunteers2
1TerminatedTreatmentHealthy Volunteers / Parkinson's Disease (PD)2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00621 mg/mLALOGPS
logP3.93ALOGPS
logP2.01ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)5.23ChemAxon
pKa (Strongest Basic)7.47ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area67.18 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity118.58 m3·mol-1ChemAxon
Polarizability46.9 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 09:08 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates